Daiichi to File for US Approval of New Lung Cancer Drug by March

Daiichi Sankyo Co. plans to file for US approval of its novel lung cancer drug by the end of March after the medicine showed a benefit in patients with advanced disease.

Patritumab deruxtecan was given to non-small cell lung cancer patients who had seen their cancer progress despite extensive previous treatment efforts. About 30% responded to the drug in the mid-stage trial, according to a presentation at the World Conference on Lung Cancer held in Singapore.

“These are the patients who have basically no standard of care treatment options,” Ken Takeshita, global head of research and development for ...